The mission of the Biosafety Core is two-fold. First and foremost, the core provides a fully managed, equipped, and safe working environment for the study of HIV, Mycobacterium tuberculosis (MTB) and other infectious pathogens. Secondly, the core actively develops state-of-the-art molecular methodologies for assessment of host/pathogen interactions for translational applications, such as the development of real-time quantitative PCR methodologies for the study of HIV replication and diversity in research samples. In addition, the core personnel have assumed the responsibility for training all users in good laboratory practices, periodic retraining to assure compliance with laboratory regulations, and providing services to promote research by all investigators in the CWRU/UHC research community. Dedicated BL-3 and BL-2+ laboratories are located across from each other on the 10th floor of the Biomedical Research Building in the Division of Infectious Diseases. A five-member Biosafety Committee meets to supervise safety procedures, and a six-member Scientific Team meets to determine developmental direction by the core on a quarterly basis. The activities of this core are essential to the success of CFAR, as both safety in investigation of biohazardous pathogens and development of new methodologies to assess host/HIV interactions constitute key elements in the AIDS research efforts at CWRU/UHC. The unique aspects of the core (i.e., the ability to study the interaction between HIV and virulent Mycobacterium tuberculosis), underscores the importance of this core as a major research strength of the CWRU/UHC CFAR.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Oliveira, Vitor H F; Perazzo, Joseph D; Josephson, Richard A et al. (2018) Association Between the 6-Minute Walk Test Distance and Peak Cardiorespiratory Fitness Among People Living with HIV Varies by Fitness Level. J Assoc Nurses AIDS Care 29:775-781
Paparisto, Ermela; Woods, Matthew W; Coleman, Macon D et al. (2018) Evolution-Guided Structural and Functional Analyses of the HERC Family Reveal an Ancient Marine Origin and Determinants of Antiviral Activity. J Virol 92:
Llewellyn, George N; Alvarez-Carbonell, David; Chateau, Morgan et al. (2018) HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J Neurovirol 24:192-203
Longenecker, Chris T; Sullivan, Claire E; Morrison, Justin et al. (2018) The effects of HIV and smoking on aortic and splenic inflammation. AIDS 32:89-94
Tomas, Myreen E; Mana, Thriveen S C; Wilson, Brigid M et al. (2018) Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice. Antimicrob Agents Chemother 62:
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Sahmoudi, Karima; Abbassi, Hassan; Bouklata, Nada et al. (2018) Immune activation and regulatory T cells in Mycobacterium tuberculosis infected lymph nodes. BMC Immunol 19:33
Webel, Allison R; Moore, Shirley M; Longenecker, Chris T et al. (2018) Randomized Controlled Trial of the SystemCHANGE Intervention on Behaviors Related to Cardiovascular Risk in HIV+ Adults. J Acquir Immune Defic Syndr 78:23-33
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Eckard, Allison Ross; O'Riordan, Mary Ann; Rosebush, Julia C et al. (2018) Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth. Antivir Ther 23:315-324

Showing the most recent 10 out of 539 publications